Skip to main content

Paion Value Stock - Dividend - Research Selection

Paion

ISIN: DE000A0B65S3, WKN: A0B65S

Market price date: 23.07.2021
Market price: 1,80 EUR




Paion Fundamental data and company key figures of the share

Annual reports in EUR
Key figures 02-11-2020
Cash flow
Net operating cash flow -2.846.930
Capital Expenditures -15.260
Free cash flow -2.862.190
Balance sheet
Total Equity 14.732.500
Liabilities & Shareholders equity 24.911.800
Income statement
Net income -7.015.820
Eps (diluted) -0,110
Diluted shares outstanding 63.918.000
Net sales/revenue 8.000.000

Fundamental ratios calculated on: 23-07-2021

Ratios
Key figures 23-07-2021
Cash flow
P/C -40,41
   
P/FC -40,20
Balance sheet
ROI-28,16
ROE59,14
Income statement
P/E-16,36
Div. Yield0,00%
P/B7,81
P/S14,38


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
SymbolPA8.XETRA
Market Capitalization139.542.032,00 USD
Country
IndicesCDAX
Sectors
Raw Data SourceIFRS in Millionen EUR
Stock Split2021-03-24,971.000000/954.000000; 2017-02-10,612.000000/607.000000; 2014-06-20,599.000000/538.000000; 2013-12-23,818.000000/795.000000
Internethttp://www.paion.com


Description of the company

Paion AG, a specialty pharmaceutical company, develops and commercializes drugs for out-patient and hospital-based sedation, anesthesia, and critical care services worldwide. The company's lead product is Remimazolam, an ultra-short-acting intravenous benzodiazepine sedative/anesthetic, which is in final stage of clinical development for use in procedural sedation, as well as in other indications, such as general anesthesia and intensive care unit sedation. It has partnerships and license agreements with Cosmo Pharmaceuticals, Yichang Humanwell, R-Pharm, TR-Pharm, Hana Pharm, Pharmascience, and Mundipharma. Paion AG was founded in 2000 and is based in Aachen, Germany.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov, http://www.paion.com